Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
MYL [NASD]
Mylan N.V.
IndexS&P 500 P/E29.94 EPS (ttm)0.52 Insider Own1.38% Shs Outstand516.90M Perf Week-0.13%
Market Cap8.06B Forward P/E3.36 EPS next Y4.66 Insider Trans0.18% Shs Float510.93M Perf Month10.42%
Income270.50M PEG12.74 EPS next Q1.16 Inst Own91.20% Short Float8.82% Perf Quarter-3.27%
Sales11.50B P/S0.70 EPS this Y-95.00% Inst Trans-0.75% Short Ratio9.32 Perf Half Y-2.79%
Book/sh22.72 P/B0.69 EPS next Y3.44% ROA0.90% Target Price22.00 Perf Year-14.03%
Cash/sh0.78 P/C20.10 EPS next 5Y2.35% ROE2.30% 52W Range12.75 - 23.11 Perf YTD-21.94%
Dividend- P/FCF4.91 EPS past 5Y-58.00% ROI2.30% 52W High-32.11% Beta1.47
Dividend %- Quick Ratio0.50 Sales past 5Y8.30% Gross Margin40.40% 52W Low23.06% ATR0.51
Employees35000 Current Ratio0.90 Sales Q/Q-4.20% Oper. Margin7.70% RSI (14)53.80 Volatility3.20% 3.02%
OptionableYes Debt/Eq1.03 EPS Q/Q123.30% Profit Margin2.40% Rel Volume0.52 Prev Close15.60
ShortableYes LT Debt/Eq0.77 EarningsAug 06 BMO Payout0.00% Avg Volume4.84M Price15.69
Recom2.30 SMA203.08% SMA500.96% SMA200-6.95% Volume2,527,281 Change0.58%
Jan-27-20Downgrade SVB Leerink Outperform → Mkt Perform $24
Jan-09-20Initiated Piper Sandler Neutral $21
Nov-07-19Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-05-19Downgrade CFRA Hold → Sell
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Oct-23-20 09:50AM  
Oct-21-20 01:41PM  
Oct-12-20 03:15AM  
Oct-09-20 11:48AM  
Oct-07-20 07:49AM  
07:00AM  
Oct-06-20 04:38PM  
Sep-25-20 01:19PM  
Sep-18-20 07:13AM  
Sep-17-20 09:51AM  
Sep-16-20 10:29AM  
Sep-15-20 07:15AM  
07:00AM  
Sep-10-20 06:05AM  
Sep-09-20 06:36PM  
03:52PM  
01:07PM  
01:05PM  
Sep-08-20 03:13PM  
09:11AM  
06:24AM  
02:00AM  
Sep-05-20 11:32AM  
Sep-03-20 07:00AM  
Sep-01-20 04:38PM  
Aug-31-20 06:00AM  
Aug-28-20 06:30PM  
11:35AM  
Aug-26-20 09:22AM  
Aug-25-20 09:33AM  
Aug-24-20 09:36AM  
Aug-23-20 12:46PM  
Aug-21-20 11:32AM  
07:30AM  
Aug-20-20 11:00AM  
Aug-19-20 02:26PM  
10:57AM  
07:00AM  
Aug-18-20 11:09AM  
Aug-17-20 10:05AM  
Aug-13-20 04:39PM  
12:14AM  
Aug-12-20 03:38PM  
09:00AM  
Aug-11-20 10:28AM  
Aug-09-20 01:15PM  
Aug-06-20 01:24PM  
07:45AM  
06:56AM  
06:46AM  
06:41AM  
06:30AM  
Aug-04-20 04:59PM  
Aug-02-20 10:05AM  
Jul-30-20 12:33PM  
11:00AM  
Jul-29-20 12:10PM  
Jul-28-20 08:59AM  
Jul-27-20 10:00AM  
Jul-22-20 07:30AM  
05:59AM  
05:50AM  
Jul-21-20 06:40PM  
Jul-20-20 08:00AM  
Jul-18-20 01:45PM  
Jul-17-20 09:00AM  
Jul-16-20 12:29AM  
Jul-15-20 05:55PM  
Jul-14-20 09:00AM  
Jul-10-20 10:24AM  
09:00AM  
Jul-09-20 07:15PM  
07:15PM  
05:45PM  
08:30AM  
06:30AM  
Jul-08-20 05:50PM  
08:59AM  
Jul-07-20 07:03PM  
04:44PM  
12:49PM  
11:35AM  
10:25AM  
06:14AM  
Jul-06-20 04:20PM  
03:39PM  
01:05PM  
12:12PM  
07:14AM  
07:14AM  
07:07AM  
06:00AM  
04:16AM  
01:30AM  
Jul-04-20 04:40PM  
Jul-03-20 12:27PM  
11:00AM  
Jul-02-20 04:51PM  
02:50PM  
02:40PM  
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PARRISH MARK WDirectorAug 11Buy16.7912,500209,83058,295Aug 12 06:02 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.0019,3670125,321Mar 04 06:31 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.0013,945039,476Mar 04 06:33 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0070,4960302,999Mar 04 06:38 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200583Mar 04 06:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002,906031,238Mar 04 06:32 PM
Malik RajivPresidentMar 03Option Exercise0.0043,3830283,195Mar 04 06:41 PM
PARRISH MARK WDirectorMar 02Option Exercise0.006,011045,795Mar 04 06:48 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.006,011050,217Mar 04 06:44 PM
Malik RajivPresidentMar 02Option Exercise0.0048,1610260,076Mar 04 06:41 PM
Campbell PaulSee RemarksMar 02Option Exercise0.005510494Mar 04 06:32 PM
Campbell PaulSee RemarksMar 02Option Exercise0.006,109030,550Mar 04 06:32 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.006,011053,017Mar 04 06:32 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.006,011048,269Mar 04 06:33 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.006,011039,131Mar 04 06:30 PM
Cindrich Robert JDirectorMar 02Option Exercise0.006,011027,479Mar 04 06:31 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0073,2130264,089Mar 04 06:38 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.006,01108,695Mar 04 06:37 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.006,011018,039Mar 04 06:35 PM
MARK RICHARD ADirectorMar 02Option Exercise0.009,007013,007Mar 04 06:35 PM
KORMAN HARRYDirectorMar 02Option Exercise0.006,011028,945Mar 04 06:35 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.0021,646034,082Mar 04 06:33 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.0021,6460115,119Mar 04 06:31 PM
Campbell PaulSee RemarksFeb 05Sale23.0011,611267,05325,413Feb 07 06:00 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.